Showing 1–25 of 145 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Álvaro H Borges, Marisa Russell, Dereck Tait, Thomas J Scriba, Elisa Nemes, et al.
**BACKGROUND:** People with tuberculosis who complete treatment remain at risk of recurrent disease. The vaccine H56:IC31 has been shown to be safe and immunogenic in phase 1 and 2 studies, but whether it can reduce the risk of tuberculosis recurrence is unknown. **METHODS:** In…
Shivangi Sinhal, Geetika Srivastava, Shrish Bhatnagar, Nanda Chhavi, Digvijay Chaudhary, et al.
…ection is highly prevalent in our country and conversion to tuberculosis disease is a major concern. Under the National Strategic Plan, India is heading towards ending tuberculosis by 2025. The benefits of tuberculosis preventive therapy are being extended to the children aged &#…
Robert Akpata, Jean-Baptiste Ntakpe, Eugène Messou, Nathalie De Castro, Corine Chazallon, et al.
**BACKGROUND:** Tuberculosis is a severe disease, not only due to its lethality but also to a significant morbidity occurring in people living with HIV (PLWH). If factors associated to mortality, severe morbidity and unsuccessful treatment related to the host are well identified …
Angelique Kany Kany Luabeya, Virginie Rozot, Claire Imbratta, Frances Ratangee, Justin Shenje, et al.
…CKGROUND:** An effective adult vaccine is needed to control tuberculosis. We evaluated the safety and immunogenicity of a live-attenuated Mycobacterium tuberculosis vaccine (MTBVAC). **METHODS:** This single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controll…
Susan E Purchase, Joanna Brigden, James A Seddon, Neil A Martinson, Lee Fairlie, et al.
…BACKGROUND:** Young children have a high risk of developing tuberculosis (TB) disease following infection with Mycobacterium tuberculosis in the absence of preventive treatment. Infection prevalence and risk factors for infection impact delivery of prevention strategies. We aimed…
Javier Roberti, Daniela Moraes Morelli, Omar Alfonso Aguilar-Vidrio, Agnes Suyanto, Priscilla Carmiol-Rodriguez, et al.
…spectives on using a digital adherence technology (DAT) for tuberculosis (TB) treatment, specifically, the TB Treatment Support Tools (TB-TST) intervention, which integrates a mobile app designed to enhance patient-centred support, monitoring and communication, alongside a drug m…
Nazir Ismail, Harry Moultrie, Judith Mwansa-Kambafwile, Andrew Copas, Alane Izu, et al.
… behavioural factors lead to poor outcomes in patients with tuberculosis. We investigated the effects of a package of interventions consisting of pre-test and post-test tuberculosis counselling with conditional cash transfers on patient outcomes in adults undergoing investigation…
Felix Gerber, Robina Semphere, Blaise Lukau, Palesa Mahlatsi, Hannah Mbale, et al.
…ral therapy (ART) should be offered to people with HIV with tuberculosis symptoms or whether ART should be initiated only after tuberculosis diagnostic results are available is unknown. This randomised trial aimed to determine whether same-day ART initiation for people with tuber…
Marc Lipman, Ibrahim Abubakar, Colin Nj Campbell, Caroline Clarke, Andrew J Copas, et al.
**BACKGROUND AND OBJECTIVES:** Tuberculosis remains a United Kingdom health concern. It occurs predominantly in people who have lived in tuberculosis endemic countries or have links there. Adherence to anti-tuberculosis treatment can be challenging, especially for people who expe…
Jayne Ellis, Gila Hale, Laura J Nsangi, Abduljewad Wele, Enos Kigozi, et al.
**BACKGROUND:** Tuberculosis preventive therapy coverage for people with advanced HIV disease (AHD) is poor. Innovative delivery strategies to increase tuberculosis preventive therapy uptake are needed; we sought to evaluate the safety and feasibility of two strategies for ultra-…
Seda Yerlikaya, Masuzyo Chirwa, Bukola Ajide, Maria Del Mar Castro, Huy Ha, et al.
**BACKGROUND:** Improved diagnostic tools for tuberculosis that are suitable for use in peripheral health centers are essential for reducing the persistent gap between estimated and notified cases. The diagnostic accuracy and usability of the MiniDock MTB test for detecting pulmo…
Cinthya Ruiz-Tagle, Romina Seguel, Luis Villarroel, Margarita Bernales, Salvador Vargas-García, et al.
…ROUND:** The duration of infectiousness following pulmonary tuberculosis treatment initiation remains uncertain. We aimed to assess whether a bundled intervention designed to decrease respiratory exposure was feasible and would reduce new tuberculosis infections in household cont…
Anushka Naidoo, Kogieleum Naidoo, Marothi P Letsoalo, Roeland E Wasmann, Gillian Dorse, et al.
…egravir-based antiretroviral therapy in people with HIV and tuberculosis has not been evaluated. We aimed to evaluate the efficacy, safety, and pharmacokinetics of bictegravir-emtricitabine-tenofovir alafenamide twice-daily in people with HIV receiving rifampicin-based tuberculos…
Betina Durovni, Marcelo Cordeiro-Santos, Solange Cesar Cavalcante, Renata Spener-Gomes, Jamile Garcia, et al.
**BACKGROUND:** Short-course tuberculosis preventive therapy with isoniazid and rifapentine (HP) is widely recommended, but the acceptability and safety of one month of daily HP (1HP) compared to three months of weekly HP (3HP) is uncertain. We compared treatment with these two r…
John Z Metcalfe, Isabelle R Weir, Kimberly K Scarsi, Alberto Mendoza-Ticona, Samuel Pierre, et al.
…ed with treatment shortening potential for drug-susceptible tuberculosis; the Clo-Fast trial aimed to determine the efficacy and safety of this regimen. We compared 3 months of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine, administered with a clofazimine load…
Ethel D Weld, Trevor Beattie, Jayajothi Moodley, Manasa Mapendere, Isadora Salles, et al.
**BACKGROUND:** Tuberculosis preventive treatment with 3 months of once-weekly isoniazid (900 mg) and rifapentine (900 mg; 3HP) is a recommended option for people with HIV; among adults with virological suppression, the 3HP regimen given with dolutegravir-based antiretroviral the…
Jayne S Sutherland, Gian D van der Spuy, Jane A Shaw, Tracy Richardson, Elisa M Tjon Kon Fat, et al.
… Non-sputum-based, point-of-care triage tests for pulmonary tuberculosis could enhance tuberculosis diagnostic programs. We assessed the diagnostic accuracy of 2 finger-stick blood tests: the Cepheid 3 gene host-response cartridge (Xpert-HR), which measures 3 host messenger RNA t…
Bart G J Dekkers, Huib A M Kerstjens, Helene W Breisnes, Diana J Leeming, Richard M Anthony, et al.
… reduce excessive inflammation and prevent tissue damage in tuberculosis are being investigated. Macrolides, including azithromycin, were shown to possess anti-inflammatory and immune-modulatory effects in addition to their antibacterial effects. In the current trial, we investig…
Nasur Buyinza, Kennedy Nkhoma, Eve Namisango, Matthew Maddocks, Julia Downing, et al.
**BACKGROUND:** People with multidrug-resistant tuberculosis experience burdensome symptoms, clinical uncertainty, and high mortality. Palliative care is a designated essential health service under Universal Health Coverage. We aimed to test the hypothesis that receipt of additio…
Alemnew F Dagnew, Linda L Han, Kogieleum Naidoo, Lee Fairlie, James C Innes, et al.
…on protein vaccine candidate derived from two Mycobacterium tuberculosis antigens (Mtb32A and Mtb39A) and AS01adjuvant. We evaluated safety and immunogenicity of M72/AS01in people living with HIV in South Africa. **METHODS:** In this observer-blinded, randomised, controlled, pha…
Ekaterina V Kurbatova, Kelly E Dooley, Wendy Carr, Jason E Stout, Eric L Nuermberger, et al.
…t shorten treatment duration for drug-susceptible pulmonary tuberculosis. **METHODS/DESIGN:** We describe the design of Tuberculosis Trials Consortium (TBTC) Study 38/CRUSH-TB (NCT05766267), an open-label multicenter international randomized controlled phase 2C trial that compar…
Lilian Tina Minja, Isabella van der Feltz, Christina Manyama, Stellah Mpagama, Francis Mhimbira, et al.
… crucial role in the first-line treatment of drug-resistant tuberculosis globally. Its prolonged use can lead to neurological and haematological toxicity, highlighting the need for safer oxazolidinones. Delpazolid, a novel oxazolidinone, might be safer. We aimed to evaluate the s…
Lorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, Maelenn Gouillou, Muhammad Hammad Ali, et al.
**BACKGROUND:** Pre-extensively drug-resistant (pre-XDR) tuberculosis (ie, multidrug-resistant or rifampicin-resistant with additional resistance to any fluoroquinolone) is difficult to treat. endTB-Q aimed to evaluate the efficacy and safety of bedaquiline, delamanid, linezolid,…
Yilin Zhang, Yang Li, Yan Ren, Ting Li, Yajiao Xing, et al.
**BACKGROUND:** Rifampicin-resistant tuberculosis (RR-TB) poses a great threat to global health. Increasing evidence of novel regimens in trial settings has risen, but the combinations of oral shorter regimens have not been optimised. An evaluation of the efficacy and safety of s…
Nestani Tukvadze, Sehlomola Mashatole, Anne Jacobs, Tlhago Ngwanto, Norbert Heinrich, et al.
**BACKGROUND:** Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide. Current TB treatments are inadequate, requiring participants closely adhere to multi-drug regimens that are long, complex, and often poorly tolerated. In addition to these well-recognized s…